Parsa Kiai Buys 4,329 Shares of Medifast (NYSE:MED) Stock

Medifast Inc (NYSE:MED) Director Parsa Kiai acquired 4,329 shares of the company’s stock in a transaction on Monday, August 24th. The stock was acquired at an average price of $12.00 per share, for a total transaction of $51,948.00. Following the purchase, the director directly owned 665,517 shares of the company’s stock, valued at approximately $7,986,204. This trade represents a 0.65% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Parsa Kiai also recently made the following trade(s):

• On Thursday, August 20th, Parsa Kiai acquired 43,150 shares of Medifast stock. The stock was acquired at an average cost of $11.60 per share, with a total value of $500,540.00.
• On Wednesday, August 19th, Parsa Kiai bought 29,337 shares of Medifast stock. The shares were acquired at an average price of $11.66 per share, with a total value of $342,069.42.

Medifast Trading Down 0.5%

MED stock opened at $12.15 on Friday. The firm has a market capitalization of $135.88 million, a PE ratio of -5.22 and a beta of 0.65. Medifast Inc has a 1-year low of $9.22 and a 1-year high of $14.67. The business’s 50 day simple moving average is $10.98 and its 200 day simple moving average is $11.09.

Medifast (NYSE:MED) last announced its quarterly earnings results on Monday, August 3rd. The specialty retailer reported ($0.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.65) by $0.37. Medifast had a negative return on equity of 6.69% and a negative net margin of 8.08%.The business had revenue of $76.38 million during the quarter, compared to the consensus estimate of $72.70 million. Medifast has set its FY 2026 guidance at -1.750–0.250 EPS and its Q3 2026 guidance at -0.650–0.150 EPS. As a group, sell-side analysts predict that Medifast Inc will post -1.04 EPS for the current fiscal year.

Trending Headlines about Medifast

Here are the key news stories impacting Medifast this week:

• Positive Sentiment: Metabolic Health Institute launched: Medifast introduced the Medifast Metabolic Health Institute to consolidate its clinical research, scientific expertise and evidence-based education. The initiative strengthens the company’s positioning in metabolic health and supports its broader transition following the launch of Trilivy™, which replaced OPTAVIA as the company’s core offering. Investors may view the institute as a long-term credibility and growth catalyst in the expanding weight-management and GLP-1 market. Medifast Announces the Launch of the Medifast Metabolic Health Institute
• Positive Sentiment: Insider continues buying: Director Parsa Kiai purchased 4,329 shares for about $51,948 at an average price of $12.00, increasing his direct ownership to 665,517 shares. The transaction follows larger purchases earlier in August and may signal management confidence in Medifast’s strategic turnaround. Medifast Director Buys 4,329 Shares
• Positive Sentiment: Earnings outlook improved: Zacks Research sharply reduced its projected losses for fiscal 2026, fiscal 2027 and fiscal 2028, forecasting EPS of negative $1.04, negative $0.47 and negative $0.43, respectively, versus prior estimates of negative $1.97, negative $1.89 and negative $1.81. Several quarterly forecasts were also raised, suggesting expectations for a faster narrowing of losses. Medifast Rating Upgrade to Buy
• Neutral Sentiment: Analyst sentiment remains mixed: Zacks upgraded the stock to Rank #2 (Buy) based on improving earnings prospects, but its analyst rating remains “Hold.” The broader consensus is still “Reduce,” with an average price target of $12.00, limiting the immediate impact of the upgrade.
• Negative Sentiment: Profitability is still weak: Medifast continues to forecast losses, while consensus calls for roughly a $1.00-per-share loss this fiscal year. Its latest quarter also produced negative EPS, net margin and return on equity, underscoring execution risk as the company shifts toward Trilivy and metabolic-health services.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in MED. BNP Paribas Financial Markets increased its position in Medifast by 103.1% during the 3rd quarter. BNP Paribas Financial Markets now owns 2,338 shares of the specialty retailer’s stock worth $32,000 after buying an additional 1,187 shares during the period. Quantbot Technologies LP acquired a new stake in shares of Medifast during the third quarter worth $37,000. Intesa Sanpaolo Wealth Management acquired a new stake in shares of Medifast during the fourth quarter worth $47,000. State of Wyoming bought a new stake in shares of Medifast in the fourth quarter valued at about $59,000. Finally, Strs Ohio bought a new stake in shares of Medifast in the first quarter valued at about $78,000. 95.51% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

MED has been the subject of several research analyst reports. Weiss Ratings raised shares of Medifast from a “sell (e+)” rating to a “sell (d)” rating in a report on Monday, August 17th. Zacks Research cut shares of Medifast from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 11th. Two equities research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Reduce” and a consensus price target of $12.00.

About Medifast

Medifast, Inc (NYSE: MED) is a health and wellness company specializing in clinically supported weight-loss, weight-management and healthy living products and services. Through its OPTAVIA brand, the company offers a range of meal replacement products, snacks, supplements and coaching programs designed to support metabolic health and sustainable lifestyle changes. Medifast markets its products directly to consumers via a network of independent distributors—known as OPTAVIA Coaches—who provide personalized guidance and support throughout the client’s weight‐loss journey.

Founded in 1980 by William Vitale and headquartered in Baltimore, Maryland, Medifast has grown into a nationally recognized provider of nutrition and weight‐management solutions.